# Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults

> **NCT05383560** · PHASE2 · COMPLETED · sponsor: **Sheba Medical Center** · enrollment: 179 (actual)

## Conditions studied

- COVID-19 Pandemic
- Immunogenicity
- SARS CoV 2 Infection
- COVID-19

## Interventions

- **BIOLOGICAL:** mRNA-1273.214 Vaccine
- **BIOLOGICAL:** MRNA-1273 Vaccine
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** MRNA-1273.222 Vaccine

## Key facts

- **NCT ID:** NCT05383560
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-05
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2024-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05383560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05383560, "Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05383560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*